Derek R Duckett

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Derek Duckett, Derek R. Duckett
Publication record
74 papers · 2,688 citations · H-index 25

PAPERS

CDK7 and CDK9 inhibition interferes with transcription, translation and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.
202311 citationsauthor #5
Abstract 3096: Development of pyrrolopyrimidine-based ACK1 inhibitors for cancer therapeutics
20230 citationsauthor #9
Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target.
20236 citationsauthor #8
Abstract B035: Targeting transcriptional elongation kinases prevents adaptation to KRASG12C inhibitors in both MAPK-dependent and -independent models of acquired resistance
20230 citationsauthor #9
Structure-Based Development of Isoform-Selective Inhibitors of Casein Kinase 1ε vs Casein Kinase 1δ.
20236 citationsauthor #9
Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics
20230 citationsauthor #8
Discovery of GSTZ1 as a novel target by using fully functionalized fragment-like probes and chemical proteomics
20220 citationsauthor #17
Abstract B028: CDK12/13 inhibition antagonizes resistance to KRASG12C inhibitors
20220 citationsauthor #8
A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma
202214 citationsauthor #17
Coordination games in cancer
202122 citationsauthor #4
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine
202118 citationsauthor #10
LMD-07. In Vitro AND In Vivo Culture of Patient Derived-Cerebral Spinal Fluid-Circulating Tumor Cells (PD-CSF-CTCs) in Leptomeningeal Disease (LMD) From Melanoma to Identify Novel Treatment Strategies
20210 citationsauthor #12
Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
202115 citationsauthor #7
Summarizing internal dynamics boosts differential analysis and functional interpretation of super enhancers
20214 citationsauthor #5
Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity
202123 citationsauthor #7
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
202110 citationsauthor #8
A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
20218 citationsauthor #7
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
202033 citationsauthor #2
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
202051 citationsauthor #12
Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase
20209 citationsauthor #13
Abstract P2-06-08: Withdrawn
20190 citationsauthor #5
βarrestin-1 regulates DNA repair by acting as an E3-ubiquitin ligase adaptor for 53BP1
201913 citationsauthor #8
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
2019223 citationsauthor #7
Abstract 3051: Targeting cdk12/13 re-sensitizes trastuzumab resistant her2+ breast cancers
20190 citationsauthor #7
Autophagy is inhibited by ubiquitin ligase activity in the nervous system
201942 citationsauthor #7
A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem Cells
201830 citationsauthor #6
Abstract 950: New strategy to sensitize pancreatic and bladder cancer to gemcitabine
20180 citationsauthor #5
Abstract B064: Therapeutic potential of CK1 delta inhibition in pancreatic and bladder cancer
20180 citationsauthor #4
Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.
201726 citationsauthor #8
In Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors.
201729 citationsauthor #6
Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors.
201711 citationsauthor #6
Design of a small molecule against an oncogenic noncoding RNA
2016169 citationsauthor #6
CK1δ: an exploitable vulnerability in breast cancer.
20162 citationsauthor #4
Identification of an EGFRvIII-JNK2-HGF/c-Met–Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion
201515 citationsauthor #9
Therapeutic targeting of casein kinase 1δ in breast cancer
201561 citationsauthor #13
Development of an HTS-Compatible Assay for the Discovery of Ulk1 Inhibitors
20159 citationsauthor #6
Antiproliferation Activity of a Small Molecule Repressor of Liver Receptor Homolog 1
201538 citationsauthor #9
Identification of an EGFRvIII-JNK 2-HGF / c-Met – Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion s
20151 citationsauthor #9
Development of an HTS-Compatible Assay for the Discovery of ASK1 Signalosome Inhibitors Using AlphaScreen Technology
20143 citationsauthor #6
Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.
201418 citationsauthor #2
Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.
20137 citationsauthor #8
Abstract C269: Targeting casein kinase 1 delta and epsilon (CK1δ/ε) in breast cancer therapeutics.
20130 citationsauthor #8
Abstract 1810: Analysis of EGFRvIII mediated responses driven by JNK2 in Glioblastoma Multiforme.
20130 citationsauthor #4
Stress-induced nuclear import of apoptosis signal-regulating kinase 1 is mediated by karyopherin α2/β1 heterodimer.
201313 citationsauthor #5
Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties.
201376 citationsauthor #13
Synthesis and SAR of 2,4-diaminopyrimidines as potent c-jun N-terminal kinase inhibitors
20125 citationsauthor #12
Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.
201169 citationsauthor #8
ASK1 and Its Role in Neurodegenerative Diseases
20114 citationsauthor #4
Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors.
201121 citationsauthor #7
Abstract 4193: Identification of a novel SIRT1/FEN1 interaction and their regulation by karyopherins
20110 citationsauthor #3
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1
2011391 citationsauthor #14
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist.
2011109 citationsauthor #6
Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.
201119 citationsauthor #12
Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
201118 citationsauthor #6
Abstract 1119: Interplay between EGFRvIII and c-Met in glioblastoma multiforme
20110 citationsauthor #4
A Predictive Nuclear Translocation Assay for Spliced X-Box–Binding Protein 1 Identifies Compounds with Known Organ Toxicities
20115 citationsauthor #3
Mechanism of oxidative stress-induced ASK1-catalyzed MKK6 phosphorylation.
201015 citationsauthor #4
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.
201062 citationsauthor #4
Metabolism considerations for kinase inhibitors in cancer treatment
2010105 citationsauthor #1
Faculty Opinions recommendation of GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
20090 citationsauthor #2
Structure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38*
200955 citationsauthor #3
Crystal structure of JNK3 with indazole inhibitor, SR-3737
20090 citationsauthor #2
Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors.
200928 citationsauthor #4
Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
200942 citationsauthor #9
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
2008283 citationsauthor #3
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.
2008142 citationsauthor #19
Chroman-3-amides as potent Rho kinase inhibitors.
200849 citationsauthor #9
Pyrimidinyl substituted amines as inhibitors of protein kinases
20080 citationsauthor #6
Synthesis of potent bicyclic bisarylimidazole c-Jun N-terminal kinase inhibitors by catalytic C-H bond activation.
200765 citationsauthor #3
Rh-Catalyzed C-H Activation Route to Bicyclic Imidazoles
20070 citationsauthor #3
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
2007150 citationsauthor #3
Identification of GSK461364, a novel small molecule polo-like kinase 1 inhibitor for the treatment of cancer
20073 citationsauthor #18
3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors.
200736 citationsauthor #2
Identification of a novel inhibitor of AKT kinase, GSK690693.
20070 citationsauthor #7

TIMELINE

2007 254 citations

2008 474 citations

2009 125 citations

2010 182 citations

2011 636 citations

2012 5 citations

2013 96 citations

2014 21 citations

2015 124 citations

2016 171 citations

2017 66 citations

2018 30 citations

2019 278 citations

2020 93 citations

2021 100 citations

2022 14 citations

2023 23 citations

COAUTHOR MAP

CONCEPT FOOTPRINT